Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10568436 | 0.93 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTCYP2D6MAPK1 | |
| SCHEMBL28470128 | 0.85 | IDO1 (0.47) | ALDH1A1LMNAMAPTMAPK1IDO1 | |
| SCHEMBL4732541 | 0.81 | NOS1 (0.43) | ALDH1A1LMNAMAPTCYP2D6MAPK1 | |
| SCHEMBL4732345 | 0.77 | NOS1 (0.47) | ALDH1A1LMNAMAPTCYP2D6MAPK1 | |
| SCHEMBL9635173 | 0.77 | CYP1A2 (0.50) | ALDH1A1LMNAMAPTCYP2D6IDO1 | |
| SCHEMBL4733905 | 0.76 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPTCYP2D6MAPK1 | |
| Bromide SCHEMBL10596031 | 0.75 | HRH4 (0.50) | ALDH1A1LMNAMAPTCYP2D6IDO1 | |
| SCHEMBL850773 | 0.74 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTCYP2D6MAPK1 | |
| SCHEMBL4730563 | 0.73 | NOS1 (0.46) | ALDH1A1LMNAMAPTCYP2D6MAPK1 | |
| SCHEMBL2379804 | 0.73 | CYP2D6 (0.46) | ALDH1A1LMNAMAPTCYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357917-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3124481-B1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2824102-B1 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-3124481-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160376252-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9481664-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9108944-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150182529-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2015-07-02 | — | — | US | disclosed |
| EP-2824102-A1 | Androgen receptor modulators and uses thereof | Aragon Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2536708-A2 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103202-A2 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2008044033-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| EP-0163416-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | disclosed |
| US-4833135-A | Antioestrogenic phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-23 | — | — | US | disclosed |
| US-4751240-A | ANTIFERTILITY AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-06-14 | — | — | US | disclosed |
| EP-0166509-A1 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-01-02 | — | — | EP | disclosed |
| EP-0163416-A2 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | ALDH1A1 853/4885LMNA 3435/4885MAPT 3119/4885 |
| US-20150182529-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | ALDH1A1 853/4885LMNA 3435/4885MAPT 3119/4885 |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | AR, ESRRA, NR5A1 | ALDH1A1 853/4885LMNA 3435/4885MAPT 3119/4885 |
| US-20160376252-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | ALDH1A1 853/4885LMNA 3435/4885MAPT 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.